billfloat

226 results found.

Top Stocks matching your search for "bill float"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

02/1002/1502/2102/2403/0103/0603/0903/1403/1703/22
SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

No reviews available.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
INM

InMed Pharmaceuticals Inc

-31.19%

$2.02 - $1.39

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

No reviews available.

02/0902/1402/1702/2302/2803/0303/0803/1303/1603/21
AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 6, 2023

$AVXL thanks yet again Bill.

Dec, 9, 2022

Worth the risk with patience and not investing lif... See more

SLRX

Salarius Pharmaceuticals Inc

-8.52%

$2.23 - $2.04

Feb 8th 2023 - Mar 22nd 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

No reviews available.

INM

InMed Pharmaceuticals Inc

-31.19%

$2.02 - $1.39

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

No reviews available.

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Feb 7th 2023 - Mar 21st 2023

Positive Reviews Happy Facepositive
Negative Reviews Sad Facenegative

Mar, 6, 2023

$AVXL thanks yet again Bill.

Dec, 9, 2022

Worth the risk with patience and not investing lifestyle or bill money.

Dec, 9, 2022

But, after cognition tests the trial passed all endpoints!

Dec, 9, 2022

THEN they said it hadnt passed any trials, well gee whiz now met BOTH secondary Endpoints. Newsflash.

Dec, 9, 2022

Blarcamesine passed every endpoints. .

Dec, 7, 2022

Key is we passed all endpoints with statically significant results!

Dec, 7, 2022

Hahah .. passed easily!

Dec, 3, 2022

Passed it all no problem!

Oct, 20, 2022

After TLR, Anavex will be the owner of a first-in-class, patented, medically-proven, high-demand asset that merely needs to pass through the technicality of government approval to qualify it for mass marketing.